Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Rapport Therapeutics will report Q1 2026 results before the market opens on May 7, with analysts expecting an EPS loss of ($0.624) and revenue of $7.5M; an earnings call is scheduled for May 8 at 9:30 AM ET.
• The company missed the prior quarter (reported ($0.72) vs. consensus ($0.65)), and analysts forecast deep negative earnings of about $-3 for the current fiscal year and $-4 for the next fiscal year.
• Insiders have sold 487,885 shares worth roughly $19.3M in the past three months (insiders own 13.57%), yet the consensus analyst rating is "Buy" with an average price target of $54.83 and several firms issuing "Buy"/"Strong Buy" ratings.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.6240) per share and revenue of $7.50 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 9:30 AM ET.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its earnings results on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.07). On average, analysts expect Rapport Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Rapport Therapeutics Price Performance

Shares of Rapport Therapeutics stock opened at $33.00 on Thursday. Rapport Therapeutics has a one year low of $7.73 and a one year high of $42.27. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -11.54 and a beta of 1.09. The business has a 50-day simple moving average of $31.54 and a 200 day simple moving average of $29.03.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $29.34, for a total transaction of $171,140.22. Following the completion of the transaction, the chief executive officer owned 556,247 shares in the company, valued at approximately $16,320,286.98. The trade was a 1.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $39.99, for a total value of $808,797.75. Following the transaction, the insider owned 246,426 shares of the company's stock, valued at $9,854,575.74. This trade represents a 7.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 487,885 shares of company stock worth $19,319,002. 13.57% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Rapport Therapeutics

A number of hedge funds have recently added to or reduced their stakes in RAPP. Vanguard Group Inc. boosted its stake in shares of Rapport Therapeutics by 46.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,626,538 shares of the company's stock worth $48,308,000 after buying an additional 519,047 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of Rapport Therapeutics by 4.1% in the 2nd quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company's stock worth $13,129,000 after buying an additional 45,063 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Rapport Therapeutics by 16.8% in the 4th quarter. Vestal Point Capital LP now owns 1,110,000 shares of the company's stock worth $33,677,000 after buying an additional 160,000 shares during the last quarter. Polar Capital Holdings Plc boosted its stake in shares of Rapport Therapeutics by 7.0% in the 4th quarter. Polar Capital Holdings Plc now owns 1,004,728 shares of the company's stock worth $30,483,000 after buying an additional 65,776 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Rapport Therapeutics by 6.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 952,371 shares of the company's stock worth $28,895,000 after buying an additional 60,113 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts recently commented on RAPP shares. Truist Financial raised Rapport Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. BTIG Research reaffirmed a "buy" rating and issued a $53.00 target price on shares of Rapport Therapeutics in a research report on Wednesday, April 22nd. Raymond James Financial started coverage on Rapport Therapeutics in a research report on Friday, April 10th. They issued a "strong-buy" rating and a $66.00 target price for the company. Wells Fargo & Company boosted their target price on Rapport Therapeutics from $43.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, March 11th. Finally, Wall Street Zen lowered Rapport Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 14th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $54.83.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.